Audentes Therapeutics, Inc. (NASDAQ:BOLD) Files An 8-K Financial Statements and Exhibits

(d) Exhibits.

Exhibit

NumberDescription

99.1Press Release issued by Audentes Therapeutics, Inc. dated September 21, 2017.

99.2Press Release issued by Audentes Therapeutics, Inc. dated September 27, 2017.

99.3Investor Presentation (INCEPTUS).

99.4Investor Presentation (LEERINK Conference).

Audentes Therapeutics, Inc. ExhibitEX-99.1 2 bold-ex991_488.htm EX-99.1 bold-ex991_488.htm   Exhibit 99.1     Audentes Therapeutics Announces Dosing of First Patient in ASPIRO,…To view the full exhibit click here
About Audentes Therapeutics, Inc. (NASDAQ:BOLD)
Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company’s subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.